Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC.Methods: A con...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-01-01
Edice:	Frontiers in Pharmacology
Témata:	hepatocellular carcinoma lenvatinib hepatitis B virus hepatitis C virus antiviral therapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1032881/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!